NCT07139990RecruitingPhase 1
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM): A Multi-cohort Platform Trial of Adaptive Radiotherapy Approaches in Multiple Cancer Types
Source: ClinicalTrials.gov · Last updated 17 Aug 2026
Brief summary (registry, in English)
To characterize feasibility, safety, and/or preliminary efficacy of personalized strategies to adapt standard radiotherapy treatments to individual patient responses.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 105 (estimated)
- First submitted
- 12 Aug 2025
- Start date
- 28 Oct 2025
- Primary completion date
- 1 Sept 2030
- Lead sponsor
- University of Texas Southwestern Medical Center
- Diseases
- Lung cancer, Sarcoma
- NCT number
- NCT07139990
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 105
- From 28 Oct 2025 to the primary completion date, 1 Sept 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- ⨀ Prior thoracic Radiotherapy
- Prior whole brain Radiotherapy
- Prior surgical resection or focal radiotherapy of a target brain metastasis
- Prior immunotherapy
- Prior systemic chemotherapy for the study cancer; prior chemotherapy for a remote cancer is allowable
- Prior immunotherapy for the study cancer or for a remote cancer
- Prior head and neck radiotherapy
Other illness
- Leptomeningeal disease
- Cohort C:
- Unresectable or metastatic (nodal or distant) disease
- Synchronous malignancy requiring chemotherapy or other intensive treatment
- HPV-positive or p16-positive oropharyngeal cancer
Other
- Cohort A:
- Cohort B:
- Locally recurrent soft tissue sarcoma
- Pregnancy or breastfeeding
- Cohort D:
- Distant metastasis
- Inability to undergo PET-CT for baseline staging
Who the study is looking for
- Cohort A:
- \>=18 years old
- Performance status ECOG 0-2
- Extensive stage small cell lung cancer diagnosed by tissue biopsy within 180 days of registration.
- Patient must be planned for or receiving standard of care chemoimmunotherapy.
- Patient must have received no more than 3 cycles by time of study enrollment.
- Able and indicated according to investigator to receive thoracic radiotherapy
- Cohort B:
- 18 years old
- Diagnosis of solid tumor malignancy with MRI-defined brain metastasis lesions within 60 days of registration
- Each brain metastasis lesion enrolled must be 2 - 5 cm, except brainstem lesions which may be 1.5 - 5cm in size.
- Cohort C:
- \>=18 years old
- Performance status ECOG 0-2
- Histologically confirmed surgically resectable, high grade (FNCLCC grade 2 or 3), localized soft tissue sarcoma of the trunk or extremities that measures \>5 cm in any direction as assessed by imaging
- Eligible to receive immunotherapy
- Cohort D:
- \>=18 years old
- Performance status ECOG 0-2
- Pathologically proven diagnosis of squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx
- Clinical stage III/IVA (AJCC 8th edition)
- Disease must be deemed resectable by head and neck surgeon
- Eligible to receive immunotherapy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UT Southwestern Medical Center Coordinator of this site? Confirm its status | Dallas | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.